

- Cervical angina syndrome, 122
- Cervical cancer, 595
- clinical features of, 595
  - deaths from, 470t, 471t
  - epidemiology of, 595, 1198
  - etiology of, 595
  - global considerations in, 595, 1198
  - in HIV infection, 1271–1272
  - HIV infection and, 1198
  - HPV in. *See* Human papillomavirus (HPV) infection, cervical cancer and
  - incidence of, 468, 471t, 595
  - KIRs with, 372e–15t
  - paraneoplastic syndromes in, 609t
  - during pregnancy, 124e–1t, 124e–2–3
  - prevention of, 478–479, 595
  - prognosis of, 593t
  - risk factors for, 27t, 595
  - screening for, 28, 29t, 84, 480, 481t, 482, 595, 1200
  - staging of, 593t, 596, 596f
  - in transplant recipient, 926
  - treatment of, 595–596
- Cervical collar, 123
- Cervical dystonia, 2620
- Cervical spine
- atlantoaxial involvement in rheumatoid arthritis, 2137
  - disk disease, 121t, 122
  - lesions of, 2651
  - trauma to, 121–122, 441e–31f
- Cervical stenosis, 338
- Cervical venous hum, 1449
- Cervicitis, mucopurulent
- C. trachomatis*, 1168–1169, 1170t
  - diagnosis of, 876, 1005
  - etiology of, 870t, 876, 876f
  - gonococcal, 1005
  - treatment of, 876
- Cervix, ectopy of, 876
- Cesarean section, 50
- CESD (cholesteryl ester storage disease), 432e–4t, 432e–5, 2443
- Cesium exposure, 263e–3t, 263e–6t
- Cestodes/cestode infections, 255e–1–2, 1430
- coenurosis, 1435
  - Diphyllobothrium latum* (fish tapeworm), 245e–2t, 645, 1434
  - Dipylidium caninum*/dipylidiasis, 1435
  - Echinococcus*. *See* Echinococcosis (hydatid disease)
  - Hymenolepis diminuta*, 1434
  - Hymenolepis nana* (dwarf tapeworm), 245e–2t, 246e–11, 1434
  - sparganosis, 1435
  - Taenia*. *See* *Taenia saginata* (beef tapeworm) infection; *Taenia solium* (pork tapeworm) infection
- CETP (cholesteryl ester transfer protein), 2438, 2438f
- CETP (cholesteryl ester transfer protein) deficiency, 2446
- CETP (cholesteryl ester transfer protein) inhibitors, 291e–6
- Cetuximab
- action and targets of, 102e–5t, 103e–21, 103e–21t
  - adverse effects of, 103e–26, 380, 505, 543, 1798
  - for colorectal cancer, 102e–5t, 103e–21, 103e–21t, 543
  - genetic variations in response to, 39t, 41
  - for head and neck cancer, 505
  - for Ménétrier's disease, 1932
  - for squamous cell carcinoma, 102e–5t
- Cevimeline, 241
- CF. *See* Cystic fibrosis (CF)
- C fibers, 87, 88
- CFM (confocal fluorescent laser microscopy), 1668
- CFTR gene mutations
- in *Aspergillus* infections, 1346
  - in cystic fibrosis, 145e–5, 429f, 435, 480e–5, 1697–1698, 1698f
  - genetic testing for, 480e–5
  - in pancreatitis, 2092, 2098–2099
  - types of, 435
  - typhoid fever resistance and, 145e–3, 442
- CFTR protein
- in cystic fibrosis, 1697, 1698f, 1700v
  - P. aeruginosa* and, 145e–4f, 145e–5, 1043
  - potentiation of, 1699
- CGDs. *See* Chronic granulomatous diseases (CGDs)
- C gene, of HBV, 2005f, 2006
- CGH (comparative genomic hybridization), 83e–3, 83e–3t
- CGRP (calcitonin gene-related peptide), 88, 444e–3, 2469
- CHADS2 score, 2564, 2566t
- Chagas' disease
- cardiac manifestations of, 1471, 1471t, 1495, 1560
  - clinical features of, 1394f, 1395
  - diagnosis of, 245e–2, 245e–4t, 245e–6t, 1395
  - differential diagnosis of, 1904
  - epidemiology of, 245e–4t, 1395
  - in HIV infection, 1265
  - pathology of, 1394, 1394f
  - prevention of, 1396
  - transfusion-associated, 138e–6, 1394
  - treatment of, 246e–8, 246e–11, 1395–1396, 1560
- Chagoma, 1395
- Chagres virus, 1309t
- Chalazion, 199
- Chamomile, 404t
- Chancre
- syphilitic, 25e–4f, 76e–9f, 237, 238t, 1134, 1134f
  - trypanosomal, 25e–12f, 1397
- Chancroid
- clinical features of, 76e–11f, 879f, 880t, 1012–1013, 1012f
  - diagnosis of, 881, 1013
  - epidemiology of, 879, 1012
  - etiology of, 1012
  - global considerations in, 879
  - in HIV infection, 1259
  - lymphadenopathy in, 408
  - treatment of, 880t, 881, 1013
- Chandipura virus, 1310t, 1316
- Channelopathy(ies)
- in cardiomyopathy, 1554, 1555t
  - muscular, 462e–16–18, 462e–17f, 462e–17t
  - neurologic, 444e–2, 444e–2t
- Chao1, 86e–4
- Chapare virus, 1306t
- Charcot-Leyden crystals, 270, 422, 1348
- Charcot-Marie-Tooth (CMT) disease
- clinical features of, 2678
  - diagnosis of, 2678
  - genetic considerations in, 434, 435, 436t, 444e–1, 2678
  - pathogenesis of, 2678
  - treatment of, 2678
- Charcot's foot, 845, 845f
- Charcot's joint (neuropathic joint disease), 1136, 2243–2244, 2243f, 2243t
- Charcot's triad, 1891, 2083
- CHARGE (coloboma of the eye, heart anomaly, choanal atresia, retardation, genital and ear anomalies) syndrome, 375e–1, 2108
- Charter on Medical Professionalism, 5
- Chart review, 25
- CHD. *See* Congenital heart disease (CHD)
- CHD7 deficiency, 375e–1, 2108
- CHD7 gene mutations, 2363, 2364t
- Chédiak-Higashi syndrome
- cellular/molecular defects in, 372e–7, 419, 420t
  - clinical features of, 236, 357t, 375e–2, 419, 420t
  - diagnosis of, 81e–2, 81e–7f, 420t, 421f
  - treatment of, 96e–5
- Cheek, traumatic lesion inside of, 46e–3f
- “Cheese effect,” 2615
- Cheese washer's lung, 1681t
- Cheilitis, 46e–2f, 501
- Cheilosis, 237, 627, 1945
- CHEK2 gene mutations, 446
- Chelation therapy, 263e–6t, 263e–7, 472e–1
- Chemical burn, oral, 239t
- Chemical restraints, 170
- Chemical terrorism, 262e–1
- characteristics and effects of, 262e–1t
  - decontamination and treatment of, 262e–2t
  - nerve agents. *See* Nerve agents vesicants. *See* Sulfur Mustard
- Chemical worker's lung, 1681, 1681t
- Chemo brain, 622
- Chemo cap, 103e–25
- Chemokine(s)
- in asthma, 1674
  - cell types, 372e–13t
  - definition of, 372e–1
  - disease connections of, 372e–13t
  - functions of, 416–417
  - in HIV infection, 1240t. *See also* CCR5 receptor
  - in pneumonia, 804
  - receptors, 372e–13t
- Chemoreceptors, 47e–1
- Chemoreceptor trigger zone (CTZ), 61, 103e–25, 258
- Chenodeoxycholic acid (CDCA), 2076
- Cherry angioma, 341t
- Cherry hemangioma, 76e–4f, 364t, 365
- Cherry red spot, 40e–4, 40e–4f, 436e–7f
- Chest compression, for cardiac arrest, 1768
- Chest discomfort/pain, 95
- approach to the patient, 98, 98t
  - cardiac biomarkers, 101
  - chest radiography, 101
  - clinical algorithms, 101, 102f
  - CMR, 102, 270e–15, 270e–15f, 270e–26v
  - CT angiography, 102, 270e–14, 270e–14f, 270e–15, 270e–16f
  - ECG, 100–101
  - echocardiography, 102, 271e–1f, 271e–1v
  - in the emergency department, 270e–15
  - history, 99–100, 99f
  - in patients with known CAD, 270e–14–15
  - in patients without known CAD, 270e–13–14, 270e–14f
  - physical examination, 100
  - stress testing, 101–102, 270e–13–14, 270e–14f
- of cardiopulmonary origin, 96t
- aortic disease, 97, 99
  - exertional, 1439
  - lung cancer, 510, 510t
  - mechanisms of, 97
  - myocardial ischemia. *See* Angina; Myocardial infarction
  - non-ischemic myocardial disease, 97
  - pericardial disease, 97, 99, 1571, 1580, 1600, 1610
  - pneumothorax, 98
  - pulmonary disease, 98
  - pulmonary embolism, 97–98
  - respiratory disease, 98, 1661
- critical pathways for, 102–103
- with dysphagia, 256
  - of emotional/psychiatric origin, 96t, 98
  - epidemiology of, 95, 95f
  - of gastrointestinal origin, 96t
  - esophageal disorders, 98, 100, 1901, 1905
  - GERD, 98, 99, 262, 1907
  - hepatobiliary disorders, 98, 100
  - pancreatitis, 98
- incidence of, 95
- of musculoskeletal origin, 96t
  - costochondritis, 98
  - herpes zoster, 98
- myocardial infarction probability with, 99f
- natural history of, 95
  - outpatient evaluation of, 103
  - in pericarditis, 1571
  - in sickle cell anemia, 634
- Chest pain units, 102–103, 1595
- Chest physiotherapy, 1696, 1699